{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:37:57Z","timestamp":1792550277782,"version":"4.5.0"},"reference-count":121,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T00:00:00Z","timestamp":1683244800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.lpm.2023.104166","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T19:08:31Z","timestamp":1683400111000},"page":"104166","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Idiopathic pulmonary fibrosis"],"prefix":"10.1016","volume":"52","author":[{"given":"Thomas","family":"Koudstaal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-6962","authenticated-orcid":false,"given":"Marlies S.","family":"Wijsenbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.lpm.2023.104166_bib0001","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"141","key":"10.1016\/j.lpm.2023.104166_bib0002","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1183\/16000617.0090-2015","article-title":"Cough in idiopathic pulmonary fibrosis","volume":"25","author":"van Manen","year":"2016","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0003","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.rmed.2015.02.002","article-title":"Natural history of idiopathic pulmonary fibrosis","volume":"109","author":"Kim","year":"2015","journal-title":"Respir Med"},{"issue":"158","key":"10.1016\/j.lpm.2023.104166_bib0004","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0154-2020","article-title":"Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis","volume":"29","author":"Cox","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1753465816686743","article-title":"Optimizing quality of life in patients with idiopathic pulmonary fibrosis","volume":"11","author":"van Manen","year":"2017","journal-title":"Ther Adv Respir Dis"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0006","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12931-019-1020-3","article-title":"The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry","volume":"20","author":"Kreuter","year":"2019","journal-title":"Respir Res"},{"key":"10.1016\/j.lpm.2023.104166_bib0007","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rmed.2018.12.015","article-title":"Inflammation and immunity in IPF pathogenesis and treatment","volume":"147","author":"Heukels","year":"2019","journal-title":"Respir Med"},{"issue":"21","key":"10.1016\/j.lpm.2023.104166_bib0008","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0009","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0010","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"9842","key":"10.1016\/j.lpm.2023.104166_bib0011","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S0140-6736(12)61144-1","article-title":"New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis","volume":"380","author":"Fernandez","year":"2012","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.lpm.2023.104166_bib0012","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1084\/jem.20110551","article-title":"Integrating mechanisms of pulmonary fibrosis","volume":"208","author":"Wynn","year":"2011","journal-title":"J Exp Med"},{"issue":"12","key":"10.1016\/j.lpm.2023.104166_bib0013","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/thoraxjnl-2016-209172","article-title":"Pulmonary fibrosis in the era of stratified medicine","volume":"71","author":"Mathai","year":"2016","journal-title":"Thorax"},{"issue":"10","key":"10.1016\/j.lpm.2023.104166_bib0014","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/jmg.2008.057356","article-title":"A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis","volume":"45","author":"Mushiroda","year":"2008","journal-title":"J Med Genet"},{"issue":"4","key":"10.1016\/j.lpm.2023.104166_bib0015","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S2213-2600(13)70045-6","article-title":"Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study","volume":"1","author":"Noth","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0016","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0017","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12863-016-0377-2","article-title":"Genome-wide imputation study identifies novel HLA locus for pulmonary fibrosis and potential role for auto-immunity in fibrotic idiopathic interstitial pneumonia","volume":"17","author":"Fingerlin","year":"2016","journal-title":"BMC Genet"},{"issue":"11","key":"10.1016\/j.lpm.2023.104166_bib0018","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/S2213-2600(17)30387-9","article-title":"Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study","volume":"5","author":"Allen","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104166_bib0019","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202207-1331OC","article-title":"Idiopathic pulmonary fibrosis is associated with common genetic variants and limited rare variants","author":"Peljto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"43","key":"10.1016\/j.lpm.2023.104166_bib0020","doi-asserted-by":"crossref","first-page":"e1901","DOI":"10.1097\/MD.0000000000001901","article-title":"Association between the MUC5B promoter polymorphism rs35705950 and idiopathic pulmonary fibrosis: a meta-analysis and trial sequential analysis in Caucasian and Asian populations","volume":"94","author":"Zhu","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0021","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12931-021-01694-z","article-title":"Prognostic role of MUC5B rs35705950 genotype in patients with idiopathic pulmonary fibrosis (IPF) on antifibrotic treatment","volume":"22","author":"Biondini","year":"2021","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0022","article-title":"Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations","volume":"1","author":"Coghlan","year":"2014","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0023","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1164\/rccm.201610-2088OC","article-title":"An exome sequencing study to assess the role of rare genetic variation in pulmonary fibrosis","volume":"196","author":"Petrovski","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.lpm.2023.104166_bib0024","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1164\/rccm.201609-1820PP","article-title":"Genetic evaluation and testing of patients and families with idiopathic pulmonary fibrosis","volume":"195","author":"Kropski","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1164\/rccm.201905-1017OC","article-title":"Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis","volume":"201","author":"Allen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.lpm.2023.104166_bib0026","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/ng.3314","article-title":"The support of human genetic evidence for approved drug indications","volume":"47","author":"Nelson","year":"2015","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0027","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01699-2018","article-title":"Idiopathic pulmonary fibrosis: unmasking cryptogenic environmental factors","volume":"53","author":"Sack","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0028","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1183\/09031936.00211311","article-title":"Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy?","volume":"39","author":"Raghu","year":"2012","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.lpm.2023.104166_bib0029","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1164\/rccm.201512-2316PP","article-title":"Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs","volume":"193","author":"Ghebre","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S2213-2600(13)70105-X","article-title":"Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials","volume":"1","author":"Lee","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"12","key":"10.1016\/j.lpm.2023.104166_bib0031","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201101-0138OC","article-title":"Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis","volume":"184","author":"Lee","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.lpm.2023.104166_bib0032","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122735","article-title":"The lung microbiome in idiopathic pulmonary fibrosis: a promising approach for targeted therapies","volume":"18","author":"Fastres","year":"2017","journal-title":"Int J Mol Sci"},{"issue":"Suppl 2","key":"10.1016\/j.lpm.2023.104166_bib0033","doi-asserted-by":"crossref","first-page":"S186","DOI":"10.1513\/AnnalsATS.201502-088AW","article-title":"Viruses in idiopathic pulmonary fibrosis. Etiology and exacerbation","volume":"12","author":"Moore","year":"2015","journal-title":"Ann Am Thorac Soc."},{"issue":"18","key":"10.1016\/j.lpm.2023.104166_bib0034","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1001\/jama.2021.4956","article-title":"Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the cleanUP-IPF randomized clinical trial","volume":"325","author":"Martinez","year":"2021","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.lpm.2023.104166_bib0035","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1001\/jama.2020.22960","article-title":"Effect of Co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: the EME-TIPAC randomized clinical trial","volume":"324","author":"Wilson","year":"2020","journal-title":"JAMA"},{"issue":"129","key":"10.1016\/j.lpm.2023.104166_bib0036","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1183\/09059180.00000713","article-title":"The role of infection in the pathogenesis of idiopathic pulmonary fibrosis","volume":"22","author":"Molyneaux","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"10","key":"10.1016\/j.lpm.2023.104166_bib0037","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","article-title":"Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model","volume":"189","author":"Selman","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.lpm.2023.104166_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072269","article-title":"Alveolar epithelial type II cells as drivers of lung fibrosis in idiopathic pulmonary fibrosis","volume":"21","author":"Parimon","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0039","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1164\/rccm.202004-1274OC","article-title":"Senescence of alveolar type 2 cells drives progressive pulmonary fibrosis","volume":"203","author":"Yao","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0040","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1164\/rccm.200810-1615OC","article-title":"Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis","volume":"181","author":"Sisson","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"20","key":"10.1016\/j.lpm.2023.104166_bib0041","doi-asserted-by":"crossref","first-page":"e90558","DOI":"10.1172\/jci.insight.90558","article-title":"Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis","volume":"1","author":"Xu","year":"2016","journal-title":"JCI Insight"},{"issue":"11","key":"10.1016\/j.lpm.2023.104166_bib0042","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/nm.4192","article-title":"Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice","volume":"22","author":"Liang","year":"2016","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0043","doi-asserted-by":"crossref","DOI":"10.3390\/cells11061050","article-title":"Emerging roles of airway epithelial cells in idiopathic pulmonary fibrosis","volume":"11","author":"Chakraborty","year":"2022","journal-title":"Cells."},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0044","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1165\/rcmb.2018-0028OC","article-title":"P311 promotes lung fibrosis via stimulation of transforming growth factor-beta1, -beta2, and -beta3 translation","volume":"60","author":"Duan","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0045","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrm809","article-title":"Myofibroblasts and mechano-regulation of connective tissue remodelling","volume":"3","author":"Tomasek","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0046","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.2353\/ajpath.2007.070112","article-title":"The myofibroblast: one function, multiple origins","volume":"170","author":"Hinz","year":"2007","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0047","first-page":"56","article-title":"Apoptosis mediates the decrease in cellularity during the transition between granulation tissue and scar","volume":"146","author":"Desmouliere","year":"1995","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0048","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1165\/rcmb.2018-0180OC","article-title":"Glutaminolysis epigenetically regulates antiapoptotic gene expression in idiopathic pulmonary fibrosis fibroblasts","volume":"60","author":"Bai","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0049","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1165\/rcmb.2017-0298OC","article-title":"Loss of CDKN2B Promotes Fibrosis via Increased Fibroblast Differentiation Rather Than Proliferation","volume":"59","author":"Scruggs","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0050","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1165\/rcmb.2017-0115OC","article-title":"R-spondin-2 is upregulated in idiopathic pulmonary fibrosis and affects fibroblast behavior","volume":"59","author":"Munguia-Reyes","year":"2018","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.lpm.2023.104166_bib0051","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1146\/annurev.med.55.091902.103810","article-title":"Mechanisms of pulmonary fibrosis","volume":"55","author":"Thannickal","year":"2004","journal-title":"Annu Rev Med"},{"issue":"7","key":"10.1016\/j.lpm.2023.104166_bib0052","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1164\/rccm.201806-1037ED","article-title":"Targeting the myofibroblast in pulmonary fibrosis","volume":"198","author":"Misharin","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0053","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144799","article-title":"Myofibroblast dedifferentiation proceeds via distinct transcriptomic and phenotypic transitions","volume":"6","author":"Fortier","year":"2021","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0054","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1165\/rcmb.2019-0092OC","article-title":"Impaired myofibroblast dedifferentiation contributes to nonresolving fibrosis in aging","volume":"62","author":"Kato","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1164\/rccm.202003-0669OC","article-title":"Monocyte count as a prognostic biomarker in patients with idiopathic pulmonary fibrosis","volume":"204","author":"Kreuter","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0056","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1615\/CritRevImmunol.v32.i6.10","article-title":"M1 and M2 macrophages: oracles of health and disease","volume":"32","author":"Mills","year":"2012","journal-title":"Crit Rev Immunol"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0057","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0116775","article-title":"Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis","volume":"10","author":"Schupp","year":"2015","journal-title":"PLoS ONE"},{"issue":"10","key":"10.1016\/j.lpm.2023.104166_bib0058","doi-asserted-by":"crossref","first-page":"5735","DOI":"10.4049\/jimmunol.176.10.5735","article-title":"Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis","volume":"176","author":"Marchal-Somme","year":"2006","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0059","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/modpathol.2011.166","article-title":"The distribution of immunomodulatory cells in the lungs of patients with idiopathic pulmonary fibrosis","volume":"25","author":"Nuovo","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.lpm.2023.104166_bib0060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2147\/JIR.S40673","article-title":"Lymphocyte aggregates persist and accumulate in the lungs of patients with idiopathic pulmonary fibrosis","volume":"6","author":"Todd","year":"2013","journal-title":"J Inflamm Res"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0061","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1183\/09031936.98.11030706","article-title":"Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis","volume":"11","author":"Fireman","year":"1998","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lpm.2023.104166_bib0062","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3389\/fimmu.2016.00516","article-title":"Skewed lung CCR4 to CCR6 CD4(+) T cell ratio in idiopathic pulmonary fibrosis is associated with pulmonary function","volume":"7","author":"Adegunsoye","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.lpm.2023.104166_bib0063","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2014.08.003","article-title":"B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis","volume":"56","author":"Francois","year":"2015","journal-title":"J Autoimmun"},{"issue":"7","key":"10.1016\/j.lpm.2023.104166_bib0064","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1164\/rccm.201104-0668OC","article-title":"Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study","volume":"184","author":"Lamas","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0065","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.rmed.2013.09.002","article-title":"A cohort study of interstitial lung diseases in central Denmark","volume":"108","author":"Hyldgaard","year":"2014","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0066","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12890-017-0560-x","article-title":"Barriers to timely diagnosis of interstitial lung disease in the real world: the INTENSITY survey","volume":"18","author":"Cosgrove","year":"2018","journal-title":"BMC Pulm Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0067","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.rmed.2006.10.002","article-title":"Patient experiences with pulmonary fibrosis","volume":"101","author":"Collard","year":"2007","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.lpm.2023.104166_bib0068","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/1479972311416382","article-title":"Living with idiopathic pulmonary fibrosis: an in-depth qualitative survey of European patients","volume":"8","author":"Schoenheit","year":"2011","journal-title":"Chron Respir Dis"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0069","article-title":"Baseline clinical characteristics, comorbidities and prescribed medication in a real-world population of patients with idiopathic pulmonary fibrosis: the PROOF registry","volume":"5","author":"Wuyts","year":"2018","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12931-019-1076-0","article-title":"Risk factors for diagnostic delay in idiopathic pulmonary fibrosis","volume":"20","author":"Hoyer","year":"2019","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0071","article-title":"Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates","volume":"9","author":"Hoyer","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0072","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0073","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtcvs.2014.12.057","article-title":"Diagnostic yield and postoperative mortality associated with surgical lung biopsy for evaluation of interstitial lung diseases: a systematic review and meta-analysis","volume":"149","author":"Han","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0074","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1159\/000484055","article-title":"Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the cryobiopsy working group on safety and utility and a call for standardization of the procedure","volume":"95","author":"Hetzel","year":"2018","journal-title":"Respiration"},{"issue":"166","key":"10.1016\/j.lpm.2023.104166_bib0075","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0280-2021","article-title":"Diagnostic yield and safety of transbronchial lung cryobiopsy and surgical lung biopsy in interstitial lung diseases: a systematic review and meta-analysis","volume":"31","author":"Rodrigues","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"11","key":"10.1016\/j.lpm.2023.104166_bib0076","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1513\/AnnalsATS.201612-947OC","article-title":"Usual interstitial pneumonia can be detected in transbronchial biopsies using machine learning","volume":"14","author":"Pankratz","year":"2017","journal-title":"Ann Am Thorac Soc."},{"issue":"10","key":"10.1016\/j.lpm.2023.104166_bib0077","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1164\/rccm.202009-3608ST","article-title":"Home oxygen therapy for adults with chronic lung disease. An official American thoracic society clinical practice guideline","volume":"202","author":"Jacobs","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0078","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/resp.13002","article-title":"Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia","volume":"22","author":"Dowman","year":"2017","journal-title":"Respirology"},{"issue":"7","key":"10.1016\/j.lpm.2023.104166_bib0079","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/thoraxjnl-2016-208638","article-title":"The evidence of benefits of exercise training in interstitial lung disease: a randomised controlled trial","volume":"72","author":"Dowman","year":"2017","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0080","article-title":"Pulmonary rehabilitation for interstitial lung disease","volume":"2","author":"Dowman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0081","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.rmed.2011.11.014","article-title":"Predictors of benefit following pulmonary rehabilitation for interstitial lung disease","volume":"106","author":"Holland","year":"2012","journal-title":"Respir Med"},{"issue":"156","key":"10.1016\/j.lpm.2023.104166_bib0082","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0125-2019","article-title":"The supportive care needs of people living with pulmonary fibrosis and their caregivers: a systematic review","volume":"29","author":"Lee","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0083","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/10499091211041724","article-title":"Advance care planning needs in idiopathic pulmonary fibrosis: a qualitative study","volume":"39","author":"Kalluri","year":"2022","journal-title":"Am J Hosp Palliat Care"},{"issue":"8","key":"10.1016\/j.lpm.2023.104166_bib0084","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1159\/000516291","article-title":"The value of the surprise question to predict one-year mortality in idiopathic pulmonary fibrosis: a prospective cohort study","volume":"100","author":"Moor","year":"2021","journal-title":"Respiration"},{"issue":"10","key":"10.1016\/j.lpm.2023.104166_bib0085","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The international thoracic organ transplant registry of the international society for heart and lung transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match","volume":"38","author":"Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"161","key":"10.1016\/j.lpm.2023.104166_bib0086","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0017-2021","article-title":"Lung transplantation for interstitial lung disease","volume":"30","author":"Kapnadak","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"11","key":"10.1016\/j.lpm.2023.104166_bib0087","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the international society for heart and lung transplantation","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"22","key":"10.1016\/j.lpm.2023.104166_bib0088","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.lpm.2023.104166_bib0089","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0090","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1164\/rccm.201701-0091OC","article-title":"Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis","volume":"196","author":"Ley","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0091","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1164\/rccm.201503-0562OC","article-title":"Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS","volume":"193","author":"Costabel","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0092","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S2213-2600(16)30326-5","article-title":"Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis","volume":"5","author":"Nathan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104166_bib0093","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rmed.2016.02.001","article-title":"Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS(R) trials","volume":"113","author":"Richeldi","year":"2016","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0094","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12931-014-0157-3","article-title":"Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis","volume":"15","author":"Hostettler","year":"2014","journal-title":"Respir Res"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0095","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12931-017-0654-2","article-title":"Anti-fibrotic efficacy of nintedanib in pulmonary fibrosis via the inhibition of fibrocyte activity","volume":"18","author":"Sato","year":"2017","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0096","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1124\/jpet.113.208223","article-title":"Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis","volume":"349","author":"Wollin","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.lpm.2023.104166_bib0097","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2017.07.062","article-title":"Therapeutic targets in idiopathic pulmonary fibrosis","volume":"131","author":"Kolb","year":"2017","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0098","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.chest.2015.11.013","article-title":"Drug treatment of idiopathic pulmonary fibrosis: systematic review and network meta-analysis","volume":"149","author":"Canestaro","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.lpm.2023.104166_bib0099","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12916-016-0558-x","article-title":"Treatment of idiopathic pulmonary fibrosis: a network meta-analysis","volume":"14","author":"Rochwerg","year":"2016","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1164\/rccm.201411-2044ED","article-title":"Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions","volume":"191","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0101","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1183\/13993003.01030-2015","article-title":"FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis","volume":"47","author":"Raghu","year":"2016","journal-title":"Eur Respir J"},{"issue":"12","key":"10.1016\/j.lpm.2023.104166_bib0102","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1021\/acsmedchemlett.7b00312","article-title":"Discovery of BI-2545: a novel autotaxin inhibitor that significantly reduces LPA levels in Vivo","volume":"8","author":"Kuttruff","year":"2017","journal-title":"ACS Med Chem Lett"},{"issue":"7","key":"10.1016\/j.lpm.2023.104166_bib0103","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1080\/13543776.2017.1323331","article-title":"Autotaxin inhibitors: a patent review (2012-2016)","volume":"27","author":"Nikolaou","year":"2017","journal-title":"Expert Opin Ther Pat"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0104","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.chest.2018.08.1058","article-title":"Randomized, double-blind, placebo-controlled, phase 2 trial of BMS-986020, a lysophosphatidic acid receptor antagonist for the treatment of idiopathic pulmonary fibrosis","volume":"154","author":"Palmer","year":"2018","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0105","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s00228-018-2435-3","article-title":"Safety, tolerability and pharmacokinetics of GSK3008348, a novel integrin alphavbeta6 inhibitor, in healthy participants","volume":"74","author":"Maden","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0106","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1164\/rccm.202107-1766OC","article-title":"Efficacy of inhaled treprostinil on multiple disease progression events in patients with pulmonary hypertension due to parenchymal lung disease in the INCREASE Trial","volume":"205","author":"Nathan","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0107","article-title":"Study design and rationale for the TETON phase 3, randomised, controlled clinical trials of inhaled treprostinil in the treatment of idiopathic pulmonary fibrosis","volume":"9","author":"Nathan","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.lpm.2023.104166_bib0108","article-title":"Management of acute exacerbation of idiopathic pulmonary fibrosis in specialised and non-specialised ILD centres around the world","volume":"8","author":"Polke","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0109","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-2600(21)00354-4","article-title":"Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"10","author":"Naccache","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.lpm.2023.104166_bib0110","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.lpm.2023.104166_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173508","article-title":"A novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung","volume":"885","author":"Matsuhira","year":"2020","journal-title":"Eur J Pharmacol"},{"issue":"20","key":"10.1016\/j.lpm.2023.104166_bib0112","doi-asserted-by":"crossref","first-page":"e87446","DOI":"10.1172\/jci.insight.87446","article-title":"Pentraxin-2 suppresses c-Jun\/AP-1 signaling to inhibit progressive fibrotic disease","volume":"1","author":"Nakagawa","year":"2016","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.lpm.2023.104166_bib0113","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1183\/13993003.00850-2015","article-title":"Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy","volume":"47","author":"van den Blink","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0114","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02559-2020","article-title":"Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosis","volume":"57","author":"Hirani","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.lpm.2023.104166_bib0115","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ajpath.2018.01.009","article-title":"A newly discovered antifibrotic pathway regulated by two fatty acid receptors: GPR40 and GPR84","volume":"188","author":"Gagnon","year":"2018","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0116","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s40169-016-0117-2","article-title":"JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers","volume":"5","author":"van der Velden","year":"2016","journal-title":"Clin Transl Med"},{"issue":"1","key":"10.1016\/j.lpm.2023.104166_bib0117","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1124\/pr.114.009381","article-title":"The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis","volume":"67","author":"Knipe","year":"2015","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.lpm.2023.104166_bib0118","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S2213-2600(21)00503-8","article-title":"Proteomic biomarkers of progressive fibrosing interstitial lung disease: a multicentre cohort analysis","volume":"10","author":"Bowman","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.lpm.2023.104166_bib0119","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.202105-1193ST","article-title":"Patient-centered outcomes research in interstitial lung disease: an official american thoracic society research statement","volume":"204","author":"Aronson","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"18","key":"10.1016\/j.lpm.2023.104166_bib0120","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lpm.2023.104166_bib0121","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00475-1","article-title":"Usual interstitial pneumonia as a stand-alone diagnostic entity: the case for a paradigm shift?","author":"Selman","year":"2023","journal-title":"Lancet Respir Med"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498223000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:08:26Z","timestamp":1760105306000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498223000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0755498223000039"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104166","relation":{},"ISSN":["0755-4982"],"issn-type":[{"value":"0755-4982","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Idiopathic pulmonary fibrosis","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2023.104166","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"104166"}}